Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: PBI19 BUDGET IMPACT ANALYSIS OF IXEKIZUMAB, GUSELKUMAB, RISANKIZUMAB AND/OR SECUKINUMAB FOR MANAGEMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE KINGDOM OF SAUDI ARABIA, Value in Health, May 2020, Elsevier,
DOI: 10.1016/j.jval.2020.04.086.
You can read the full text:

Read

Contributors

The following have contributed to this page